CRON:NSD-Cronos Group Inc (USD)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 2.61

Change

-0.09 (-3.33)%

Market Cap

USD 1.00B

Volume

4.98M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-03-28 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
NBIX Neurocrine Biosciences Inc

-1.77 (-1.28%)

USD 14.07B
VTRS Viatris Inc

+0.10 (+0.87%)

USD 13.36B
ITCI Intracellular Th

+1.13 (+1.57%)

USD 6.68B
ALKS Alkermes Plc

+0.24 (+0.98%)

USD 4.18B
LNTH Lantheus Holdings Inc

+0.36 (+0.55%)

USD 4.05B
ALVO Alvotech

+0.50 (+3.66%)

USD 3.82B
INDV Indivior PLC Ordinary Shares

+0.33 (+1.91%)

USD 2.93B
HCM HUTCHMED DRC

-0.83 (-4.37%)

USD 2.80B
EVO Evotec SE ADR

-0.08 (-1.57%)

USD 2.51B
AMPH Amphastar P

+0.28 (+0.69%)

USD 2.00B

ETFs Containing CRON

HMMJ-U:CA Horizons Marijuana Life S.. 14.24 % 0.00 %

N/A

CAD 0.09B
YOLO AdvisorShares Pure Cannab.. 4.50 % 0.00 %

+0.07 (+0%)

USD 0.05B
CNBS Amplify Seymour Cannabis .. 3.86 % 0.00 %

+0.09 (+0%)

USD 0.03B
BUDX 3.84 % 0.00 %

N/A

N/A
PSY 0.00 % 0.76 %

N/A

N/A
MJ Amplify Alternative Harve.. 0.00 % 0.75 %

+0.12 (+0%)

USD 0.23B
SEED:CA 0.00 % 1.13 %

N/A

N/A
THCX 0.00 % 0.00 %

N/A

N/A
HMMJ:CA Horizons Marijuana Life S.. 0.00 % 0.86 %

+0.08 (+0%)

CAD 0.08B
POTX 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 24.88% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 24.88% 77% C+ 84% B
Trailing 12 Months  
Capital Gain 38.10% 76% C+ 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 38.10% 76% C+ 82% B
Trailing 5 Years  
Capital Gain -85.84% 38% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -85.84% 38% F 12% F
Average Annual (5 Year Horizon)  
Capital Gain -25.90% 33% F 14% F
Dividend Return -25.90% 33% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 37.73% 65% D 48% F
Risk Adjusted Return -68.65% 35% F 15% F
Market Capitalization 1.00B 76% C+ 73% C

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector